Clinical Trials Logo

Clinical Trial Summary

A timing diagnosis of candidemia is as important as the correct choice of empiric or targeted antifungal therapy. In the last years a growing body of knowledge has better characterized health-care associated (HCA) infections, which have been described in 2002 in outpatients with MRSA bloodstream infections. So far there is no compelling evidence that patients with HCA infections may develop candidemia before the usual timing of around 20-25 days after admission. Risk factors associated with HCA infections are represented by admission from long term chronic care facilities (LTCF), haemodialysis, previous admission or parenteral broad spectrum antibiotics. There are few data HCA features and early onset candidemias in the published literature.

In this proposal, the investigators aim at studying early-onset candidemia in a retrospective study in one of the largest referral hospital in Italy with a consistent range of specialties ranging (bone marrow transplant, solid organ transplant, immunosuppressed patients, ICU, complex surgery). The investigators speculate that patients with candidemia diagnosed within 10 days (early-onset) by the admission have different risk factors and prognosis of those with a late diagnosis.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01406093
Study type Observational
Source University of Turin, Italy
Contact
Status Completed
Phase N/A
Start date May 2011
Completion date June 2012

See also
  Status Clinical Trial Phase
Terminated NCT01982071 - A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Phase 4
Completed NCT02244606 - Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Phase 2
Completed NCT02163889 - Serial Therapeutic and Antifungal Monitoring Protocol
Recruiting NCT01438216 - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients N/A
Not yet recruiting NCT01249313 - Risk Factor and Outcome of Candidemia N/A
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Terminated NCT01213823 - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Phase 4
Completed NCT00105144 - Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Phase 3
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT03604705 - An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia Phase 2
Completed NCT00607763 - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00608335 - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Recruiting NCT04147975 - Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
Completed NCT01734525 - Negative Beta Glucan in ICU Patients Phase 4
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT03363841 - Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) Phase 3
Completed NCT03799172 - Echinocandins Versus Azoles for Candidemia Treatment
Completed NCT00670657 - CRITIC - Treatment of Candidemia and Invasive Candidiasis Phase 4
Completed NCT00113191 - Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants N/A
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3